News

As Ranbaxy Laboratories laid out some of the actions it has taken “to address certain conduct of the past” to ensure the safety of its products, reports are circulating that the Indian drugmaker could shed up to a third of its salesforce.

Companies and individuals have been recognised for their excellence in advancing the future skills required for the life sciences industry at the inaugural UK Life Sciences Skills Awards, organised by Cogent.

Merck & Co has announced the end of the line for its investigational Parkinson’s disease drug preladenant, after the drug failed to show much promise in late-stage trials.

In 2006-07, the NHS in England spent £5.6 billion on care provided by non-NHS providers, but by 2011-12 this figure had soared to £8.7 billion, according to new research.

NHS England has given the green light for 15 Academic Health Science Networks (AHSNs)* to operate across country, in line with plans laid out in Sir David Nicholson’s 2011 Innovation Health and Wealth (IHW) report.

While race and gender are often mentioned as factors complicating efforts to ensure clinical trials are conducted in representative populations, new research suggests that similar distinctions may apply to the personnel managing a clinical study.

The ABPI will represent the vaccine industry to the UK Government and healthcare stakeholders under a new deal announced this week.

Biogen Idec has filed a pegylated version of its blockbuster Avonex, called Plegridy, with the US Food and Drug Administration for relapsing forms of multiple sclerosis.

The European Commission has given the green light to Baxter International and Halozyme Therapeutics’ HyQvia as replacement therapy for adults with primary and secondary immunodeficiencies.

NICE has once again rejected Roche’s Avastin, the world’s biggest selling cancer drug, this time for its new licence in ovarian cancer. 

GlaxoSmithKline has entered into a deal with the US government to develop drugs to fight antibiotic resistance and bioterrorism.

GlaxoSmithKline is intending to close the tablet packaging section of its operations at the firm’s Boronia site in Melbourne, Australia as part of “a business transformation”.

The long-standing alliance between Sanofi and Regeneron looks to have scored another clinical goal, this time with dupilumab for asthma.

Sir David Nicholson has announced that he will retire from the top job in the NHS next year after months of criticism of his managerial role at Mid Staffs.

Arrangements need to be put in place to ensure that the National Institute for Health and Care Excellence (NICE) can access all the evidence underlying product licensing decisions taken by the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA), says the National Audit Office (NAO).